{"id":1278460,"date":"2026-07-17T11:30:31","date_gmt":"2026-07-17T08:30:31","guid":{"rendered":"https:\/\/www.etoro.com\/?p=1278460"},"modified":"2026-07-17T18:36:30","modified_gmt":"2026-07-17T15:36:30","slug":"deep-dive-eli-lillys-record-run-and-reset-valuation","status":"publish","type":"post","link":"https:\/\/www.etoro.com\/en-us\/news-and-analysis\/market-insights\/deep-dives\/deep-dive-eli-lillys-record-run-and-reset-valuation\/","title":{"rendered":"Deep Dive: Eli Lilly\u2019s Record Run and Reset Valuation"},"content":{"rendered":"

Before we dive in, let\u2019s make sure you\u2019re set to receive The Daily Breakdown each morning. <\/span><\/i>To keep getting our daily insights<\/i><\/b>, all you need to do is <\/span><\/i>log in<\/span><\/i><\/a> to your eToro account.<\/span><\/i><\/p>\n

Interested in more Deep Dive content? Check out <\/span><\/i>our latest research<\/span><\/i><\/a>.\u00a0<\/span><\/i><\/p>\n

Deep Dive<\/b><\/h2>\n

Eli Lilly<\/a> is one of the world\u2019s largest pharmaceutical companies, with a market value of roughly $1.1 trillion. It develops medicines across diabetes, obesity, cancer, immunology, and neuroscience, but is best known today for Mounjaro and Zepbound, its blockbuster treatments for diabetes and weight loss. Those drugs have become the company\u2019s main growth engine, supported by products such as Verzenio, Jardiance, Taltz, and Alzheimer\u2019s treatment Kisunla.<\/span><\/p>\n

Its pipeline is led by next-generation obesity drugs, including retatrutide, as well as efforts to expand tirzepatide into additional metabolic and cardiovascular conditions. Lilly is also developing new treatments for Alzheimer\u2019s disease, cancer, and inflammatory disorders.<\/span><\/p>\n

\"\"<\/p>\n

Revenue has grown for eight straight years and is expected to keep rising. Profits have been less consistent, with sharp gains often followed by flat or weaker years. The chart above adds context through operating margins and ROIC, or how efficiently invested capital generates profit.<\/span><\/p>\n

In other words, the company\u2019s margin profile has strengthened over the last few years, while Eli Lilly has seen improved returns on its investments.\u00a0<\/span><\/p>\n

Future Growth Projections<\/b><\/h3>\n

Over the last three months and six months, earnings estimates for LLY have been revised higher by 4.3% and 7.1%, respectively. As earnings and revenue have improved over the past few years, analysts expect that to continue moving forward. According to Bloomberg, analysts project the following:<\/span><\/p>\n